At least two experimental COVID-19 vaccines produced a T-cell response in participants in early-stage clinical trials, which may indicate a longer-lasting form of immunity than an antibody response. BioNTech BNTX, + 3.46% and Pfizer Inc. PFE, + 0.69% It said early Monday morning that an ongoing early-stage clinical trial for …
Read More »Investors applaud when two coronavirus vaccine candidates report T-cell responses, but findings are still at an early stage
